Mousavi Seyed Hadi, Bakhtiari Elham, Hosseini Azar, Jamialahmadi Khadijeh
Medical Toxicology Research center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, I.R. Iran.
Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, I.R. Iran.
Res Pharm Sci. 2018 Apr;13(2):121-129. doi: 10.4103/1735-5362.223794.
Finding products with antiapoptotic activities has been one of the approaches for the treatment of neurodegenerative disorders. Serum/glucose deprivation (SGD) has been used as a model for the investigation of the molecular mechanisms of neuronal ischemia. Recent studies indicated that glucosamine (GlcN) and N-acetyl glucosamine (GlcNAc) have many pharmacological effects including antioxidant activities. The present study aimed to investigate the protective effects of GlcN and GlcNAc against SGD-induced PC12 cells injury. The PC12 cells were pretreated with GlcN and GlcNAc for 2 h, and then exposed to SGD for 6, 12 and 24 h. Cell viability was evaluated by MTT assay. The level of intracellular reactive oxygen species (ROS) was determined by flow cytometry using 2',7'- dichlorofluorescin diacetate (DCFH-DA) as a probe. SGD condition caused a significant reduction in cell survival after 6, 12, and 24 h ( < 0.001). Pretreatment with GlcN and GlcNAc (0.6-20 mM) increased cell viability following SGD insult. A significant increase in cell apoptosis was observed in cells under SGD condition after 12 h ( < 0.001). Pretreatment with GlcN and GlcNAc (5-20 mM) decreased apoptosis following SGD condition after 12 h. SGD resulted in a significant increase in intracellular ROS production after 12 h. Pretreatment with both amino sugars at concentrations of 10 to 20 mM could reverse the ROS increment. Results indicated that GlcN and GlcNAc had a cytoprotective property against SGD-induced cell death via anti-apoptosis and antioxidant activities, suggesting that these aminosugers have the potential to be used as novel therapeutic agents for neurodegenerative disorders.
寻找具有抗凋亡活性的产品一直是治疗神经退行性疾病的方法之一。血清/葡萄糖剥夺(SGD)已被用作研究神经元缺血分子机制的模型。最近的研究表明,氨基葡萄糖(GlcN)和N-乙酰氨基葡萄糖(GlcNAc)具有许多药理作用,包括抗氧化活性。本研究旨在探讨GlcN和GlcNAc对SGD诱导的PC12细胞损伤的保护作用。将PC12细胞用GlcN和GlcNAc预处理2小时,然后暴露于SGD 6、12和24小时。通过MTT法评估细胞活力。使用2',7'-二氯荧光素二乙酸酯(DCFH-DA)作为探针,通过流式细胞术测定细胞内活性氧(ROS)水平。SGD条件在6、12和24小时后导致细胞存活率显著降低(<0.001)。用GlcN和GlcNAc(0.6-20 mM)预处理可提高SGD损伤后的细胞活力。在12小时后,SGD条件下的细胞中观察到细胞凋亡显著增加(<0.001)。用GlcN和GlcNAc(5-20 mM)预处理可降低12小时后SGD条件下的细胞凋亡。SGD在12小时后导致细胞内ROS产生显著增加。用浓度为10至20 mM的两种氨基糖预处理可逆转ROS的增加。结果表明,GlcN和GlcNAc通过抗凋亡和抗氧化活性对SGD诱导的细胞死亡具有细胞保护作用,表明这些氨基糖有潜力用作神经退行性疾病的新型治疗剂。